Literature DB >> 8235624

Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.

M Howard1, J C Grimaldi, J F Bazan, F E Lund, L Santos-Argumedo, R M Parkhouse, T F Walseth, H C Lee.   

Abstract

CD38 is a 42-kilodalton glycoprotein expressed extensively on B and T lymphocytes. CD38 exhibits a structural homology to Aplysia adenosine diphosphate (ADP)-ribosyl cyclase. This enzyme catalyzes the synthesis of cyclic ADP-ribose (cADPR), a metabolite of nicotinamide adenine dinucleotide (NAD+) with calcium-mobilizing activity. A complementary DNA encoding the extracellular domain of murine CD38 was constructed and expressed, and the resultant recombinant soluble CD38 was purified to homogeneity. Soluble CD38 catalyzed the formation and hydrolysis of cADPR when added to NAD+. Purified cADPR augmented the proliferative response of activated murine B cells, potentially implicating the enzymatic activity of CD38 in lymphocyte function.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8235624     DOI： 10.1126/science.8235624

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  192 in total

1.  Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease.

Authors:  A Antonelli; P Fallahi; C Nesti; C Pupilli; P Marchetti; S Takasawa; H Okamoto; E Ferrannini
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 2.  The NAADP receptor: commentary on Billington et al.

Authors:  A Galione; J Parrington; J Dowden
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

3.  The signaling protein CD38 is essential for early embryonic development.

Authors:  Dev Churamani; Timothy J Geach; Latha Ramakrishnan; Nicole Prideaux; Sandip Patel; Leslie Dale
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

4.  miR-140-3p regulation of TNF-α-induced CD38 expression in human airway smooth muscle cells.

Authors:  Joseph A Jude; Mythili Dileepan; Subbaya Subramanian; Julian Solway; Reynold A Panettieri; Timothy F Walseth; Mathur S Kannan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-06       Impact factor: 5.464

5.  Porcine CD38 exhibits prominent secondary NAD(+) cyclase activity.

Authors:  Kai Yiu Ting; Christina F P Leung; Richard M Graeff; Hon Cheung Lee; Quan Hao; Masayo Kotaka
Journal:  Protein Sci       Date:  2016-01-12       Impact factor: 6.725

6.  Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivatives.

Authors:  T Kirchberger; G Wagner; J Xu; C Cordiglieri; P Wang; A Gasser; R Fliegert; S Bruhn; A Flügel; F E Lund; L-H Zhang; B V L Potter; A H Guse
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

7.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

8.  A monoclonal antibody against a murine CD38 homologue delivers a signal to B cells for prolongation of survival and protection against apoptosis in vitro: unresponsiveness of X-linked immunodeficient B cells.

Authors:  Y Yamashita; K Miyake; Y Kikuchi; K Takatsu; S Noda; A Kosugi; M Kimoto
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+ CD8+).

Authors:  S Castle; S Wilkins; E Heck; K Tanzy; J Fahey
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  Dual role of CD38 in microglial activation and activation-induced cell death.

Authors:  Lior Mayo; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Marie-Jo Moutin; Frances E Lund; Reuven Stein
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.